ANI Pharmaceuticals

Yahoo Finance • 6 days ago

Carlyle Group Reaches Analyst Target Price

In recent trading, shares of Carlyle Group Inc (Symbol: CG) have crossed above the average analyst 12-month target price of $40.27, changing hands for $40.96/share. When a stock reaches the target an analyst has set, the analyst logicall... Full story

Yahoo Finance • 28 days ago

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Shows Strong Momentum and Growth, Fitting Minervini's Trend-Following Criteria

ANI Pharmaceuticals Inc (NASDAQ:ANIP [https://www.chartmill.com/stock/quote/ANIP]) has become an interesting candidate for investors using Mark Minervini's trend-following method combined with high-growth momentum screening. The approach f... Full story

Yahoo Finance • 30 days ago

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executiv... Full story

Yahoo Finance • last month

Ani Pharmaceuticals stock hits 52-week high at 90.43 USD

ANI Pharmaceuticals (NASDAQ:ANIP) Inc. (market cap: $1.8 billion) has reached a significant milestone as its stock hit a 52-week high of 90.43 USD. According to InvestingPro data, the company has demonstrated impressive revenue growth of n... Full story

Yahoo Finance • last month

Ani Pharmaceuticals SVP Carey sells $4.3m in shares

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 50,000 shares of common stock on August 12, 2025, at a price of $86.07, totaling $4,303,500. On the same day, Carey also exercised options to acquire 50,000 shares... Full story

Yahoo Finance • last month

Ani Pharmaceuticals’ Cook sells $35k in stock

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 400 shares of common stock on August 13, 2025, at a price of $88.87, for a total transaction value of $35548. Following the transaction, Cook dir... Full story

Yahoo Finance • last month

Rowland, SVP at Ani Pharmaceuticals, sells $426k in stock

Thomas Andrew Rowland, SVP, HEAD - ESTABLISHED BRANDS at ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 4,975 shares of common stock on August 12, 2025, for approximately $426,407. The shares were sold in multiple transactions at prices rangi... Full story

Yahoo Finance • last month

ANI Pharmaceuticals stock price target raised to $77 from $65 at Truist Securities

Investing.com - Truist Securities raised its price target on ANI Pharmaceuticals (NASDAQ:ANIP) to $77.00 from $65.00 on Monday, while maintaining a Hold rating on the stock. The company’s shares have surged 24.53% in the past week, reachin... Full story

Yahoo Finance • 2 months ago

ANI Pharmaceuticals raises 2025 guidance to $843M revenue and $7.35 EPS as Cortrophin Gel accelerates

Earnings Call Insights: ANI Pharmaceuticals (ANIP) Q2 2025 MANAGEMENT VIEW * President and CEO Nikhil Lalwani described Q2 2025 as a "record-setting quarter for our company with all-time overall company highs in net revenue, adjusted n... Full story

Yahoo Finance • 2 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

CG Oncology Inc. - Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated CORE-008 Coho... Full story

Yahoo Finance • 2 months ago

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Reports Record Q2 2025 Earnings, Beats Estimates and Raises Full-Year Guidance

ANI Pharmaceuticals Inc (NASDAQ:ANIP [https://www.chartmill.com/stock/quote/ANIP/profile]) reported record financial results for the second quarter of 2025, significantly exceeding analyst expectations. The company also raised its full-yea... Full story

Yahoo Finance • 2 months ago

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal Rare Disease quarterly net revenues of $104.0 million, which includes: Purified... Full story

Yahoo Finance • 2 months ago

ANI Pharmaceuticals Q2 2025 Earnings Preview

* ANI Pharmaceuticals (NASDAQ:ANIP [https://seekingalpha.com/symbol/ANIP]) is scheduled to announce Q2 earnings results on Friday, August 8th, before market open. The consensus EPS Estimate is $1.42 [https://seekingalpha.com/symbol/ANIP... Full story

Yahoo Finance • 2 months ago

ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET

PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior... Full story

Yahoo Finance • 2 months ago

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A. Singe... Full story

Yahoo Finance • 3 months ago

Catalyst Watch: Amazon Prime Day, Delta earnings and stock-by-stock trade deal implications

[Business and stock exchange data on the screen.] Torsten Asmus Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next... Full story

Yahoo Finance • 3 months ago

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partne... Full story

Yahoo Finance • 3 months ago

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrop... Full story

Yahoo Finance • 4 months ago

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference... Full story

Yahoo Finance • 4 months ago

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose leve... Full story